Neal J Weinreb Selected Research

imiglucerase

1/2021	Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
3/2015	Enzyme replacement and substrate reduction therapy for Gaucher disease.
5/2013	Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
8/2012	Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
1/2011	Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
11/2009	Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
8/2008	Imiglucerase and its use for the treatment of Gaucher's disease.
2/2005	Individualization of long-term enzyme replacement therapy for Gaucher disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Neal J Weinreb Research Topics

Disease

31	Gaucher Disease (Gaucher's Disease) 12/2023 - 08/2002
3	Neoplasms (Cancer) 10/2022 - 01/2013
3	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2022 - 11/2013
3	Pain (Aches) 01/2021 - 08/2002
3	Fabry Disease (Fabry's Disease) 01/2016 - 03/2015
3	Thrombocytopenia (Thrombopenia) 08/2012 - 08/2002
2	Body Weight (Weight, Body) 01/2021 - 03/2015
2	Parkinsonian Disorders (Parkinsonism) 01/2018 - 01/2017
2	Bone Diseases (Bone Disease) 05/2015 - 01/2011
2	Anemia 08/2008 - 08/2002
1	Rare Diseases (Rare Disease) 12/2022
1	Disease Progression 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2022
1	Parkinson Disease (Parkinson's Disease) 01/2020
1	Synucleinopathies 01/2020
1	Pulmonary Hypertension 01/2018
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018
1	Liver Diseases (Liver Disease) 01/2018
1	Sepsis (Septicemia) 01/2018
1	Hemorrhage 01/2018
1	Iron Overload 01/2018
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 05/2015
1	Stroke (Strokes) 05/2015
1	Renal Insufficiency (Renal Failure) 05/2015
1	Splenomegaly 08/2012
1	Hepatomegaly 08/2012
1	Osteonecrosis (Kienbock's Disease) 08/2012
1	Metabolic Bone Diseases (Osteopenia) 01/2011
1	Necrosis 11/2009
1	Hematologic Neoplasms (Hematological Malignancy) 10/2009

Drug/Important Bio-Agent (IBA)

15	Glucosylceramidase (Glucocerebrosidase)IBA 12/2023 - 10/2004
8	imiglucerase FDA Link 01/2021 - 02/2005
7	EnzymesIBA 12/2020 - 06/2012
4	Glucosylceramides (Glucocerebrosides)IBA 12/2023 - 06/2005
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2012
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 08/2002
2	AcidsIBA 12/2023 - 01/2011
2	GlycosphingolipidsIBA 01/2022 - 01/2020
2	SynucleinsIBA 01/2022 - 01/2020
2	alglucerase FDA Link 01/2021 - 05/2013
2	agalsidase beta FDA Link 01/2016 - 05/2015
2	miglustat (Zavesca)FDA Link 03/2015 - 11/2005
2	Mannose (D-Mannose)IBA 02/2005 - 10/2004
1	Ambroxol (Mucosolvan)IBA 01/2023
1	eliglustatIBA 12/2022
1	ceramide glucosyltransferaseIBA 12/2022
1	SphingolipidsIBA 10/2022
1	LipidsIBA 01/2022
1	CalciumIBA 01/2022
1	taliglucerase alfaIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 01/2021
1	HydrolasesIBA 12/2020
1	agalsidase alfaIBA 01/2016
1	globotriaosylceramide (globotriosylceramide)IBA 05/2015
1	GalactosidasesIBA 05/2015
1	GlucosidasesIBA 01/2011
1	MineralsIBA 10/2009
1	Pain-FreeIBA 08/2002

Therapy/Procedure

15	Enzyme Replacement Therapy 05/2023 - 08/2002
12	Therapeutics 05/2023 - 08/2008
3	Splenectomy 01/2018 - 05/2015
2	Enzyme Therapy 08/2012 - 01/2011
1	Aftercare (After-Treatment) 08/2012